Natera Looks Compelling As Oncology Testing Momentum Keeps Building (NASDAQ:NTRA)

Core Insights - Natera, Inc. (NTRA) is a diagnostic company specializing in molecular testing services, with a focus on oncology, women's health, and organ health [1] - The oncology segment, particularly minimal residual disease monitoring (MRD), is the strongest area for the company [1] - In 2025, Natera plans to implement new product launches, secure new Medicare coverages, and advance its offerings [1]